These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15040573)

  • 1. 2003 approvals: a year of innovation and upward trends.
    Frantz S
    Nat Rev Drug Discov; 2004 Feb; 3(2):103-5. PubMed ID: 15040573
    [No Abstract]   [Full Text] [Related]  

  • 2. New biotechnology approvals for 2002.
    Piascik P
    J Am Pharm Assoc (Wash); 2003; 43(1):116-7. PubMed ID: 12585761
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA drug approvals: no worse is simply not good enough.
    Nat Biotechnol; 1996 Apr; 14(4):403. PubMed ID: 9630904
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech unruffled by setbacks.
    Glaser V
    Nat Biotechnol; 1997 Jul; 15(7):610-1. PubMed ID: 9219254
    [No Abstract]   [Full Text] [Related]  

  • 5. HHS: POUFA reauthorization good for Americans.
    FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
    [No Abstract]   [Full Text] [Related]  

  • 6. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 7. A piece of history.
    Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894179
    [No Abstract]   [Full Text] [Related]  

  • 8. The year in review. A panoply of product approvals.
    Nordenberg T
    FDA Consum; 2000; 34(3):10-2. PubMed ID: 11521248
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent biotechnology drug approvals.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(4):502-5. PubMed ID: 9707962
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
    Kaitin KI; DiMasi JA
    Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring emerging nanobiotechnology drugs and medical devices.
    Paradise J; Diliberto GM; Tisdale AW; Kokkoli E
    Food Drug Law J; 2008; 63(2):407-20. PubMed ID: 18561467
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 13. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 14. 2007 FDA drug approvals: a year of flux.
    Hughes B
    Nat Rev Drug Discov; 2008 Feb; 7(2):107-9. PubMed ID: 18246607
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA drug approvals in 1993-94.
    Wynn RL
    Gen Dent; 1995; 43(1):12, 14. PubMed ID: 7758913
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA drug approvals from 1994 to 1995.
    Wynn RL
    Gen Dent; 1996; 44(2):114, 116, 118. PubMed ID: 8690259
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
    Reichert JM; Paquette C
    Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defending submission-year analyses of new drug approvals.
    Carpenter DP
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W4-S3-W4-S5. PubMed ID: 15526399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA new drug approvals in 2007.
    Wynn RL
    Gen Dent; 2008; 56(6):506-10. PubMed ID: 18810906
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA new drug approvals in 2005.
    Wynn RL
    Gen Dent; 2006; 54(4):230-3. PubMed ID: 16903192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.